Treatment of Nodal Non Hodgkin Lymphoma in West Africa: Experience of Institut Curie in Dakar


In Senegal, few studies have been devoted to non-Hodgkin’s lymphoma. We conducted a retrospective descriptive study of 73 cases treated at the Institut J. Curie Hospital Aristide Le Dantec for non-Hodgkin’s lymphomas from 2001 to 2007. The main objective was to determine the clinical and therapeutic aspects. Our population consisted of 39 men and 34 women (sex ratio: 1.14). The average age was 36 years with extremes of 5 and 76 years. The most common locations were cervical (30.6%) and oropharynx (8.21%). Multiple locations were found in 30.6% of cases. Only 54.4% have histological exam. Patients were managed on cytology basis 42.6% of cases. Histology was performed in 39 patients (54.4%). Among these patients, 69% had aggressive lymphoma, of which 12.82% had a large B-cell lymphoma among indolent lymphomas (59%). The small cleaved cell lymphoma was most often found with 78.26% of cases. The patients were staged with insufficient tools. The protocol most often used was CHOP (64.3%). The most common complications reported were gastrointestinal (11%) followed by skin complications (8.2%). Radiotherapy was performed for 6 patients or 8.2% of cases. Therapeutic strategy was most often used as chemotherapy alone (69.9%). The median duration of follow-up is 18 months.

Share and Cite:

Gaye, P. , Kassé, A. , Diouf, D. , Dieng, M. and Dem, A. (2014) Treatment of Nodal Non Hodgkin Lymphoma in West Africa: Experience of Institut Curie in Dakar. Journal of Cancer Therapy, 5, 478-482. doi: 10.4236/jct.2014.55054.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Salles, G. and Coiffier, B. (1999) Lymphomes malins non hodgkiniens de haut grade de malignité. Cancers: évaluation, traitement et surveillance. 15.
[2] Bah, E., parkin, D.M., Hall, A.J., Jack, A.D. and Whittle, H. (2001) Cancer in the Gambia: 1988-97. British Journal of Cancer, 84, 1207-1214.
[3] Belot, A., Grosclaude, P., Bossard, N., Jougla, E., Benhamou, E., et al. (2008) Cancer Incidence and Mortality in France over the Period 1980-2005. Revue d’Epidémiologie et de Santé Publique, 56, 159-175.
[4] Schlaifer, D., Brousset, P. and Pris, J. (1997) Lymphome du sujet infecté par le VIH. Traité d’hématologie. 13-016-F-10, 9.
[5] Elkacimi, S. (2009) Hémopathies malines à Dakar: Aspects épidémiologiques, clinques et thérapeutiques des hémopathies malines à la Clinique Médicale I du CHU Aristide Le Dantec de Dakar. Thèse Med Dakar. 143.
[6] Fisher, R., DeVita, V., Hubbard, S., et al. (1983) Diffuse Aggressive Lymphomas: Increased Survival after Alternating Flexible Sequences of proMACE and MOPP Chemotherapy. Annals of Internal Medicine, 98, 304-309.
[7] Frei, E. and Canellos, G.P. (1980) Dose: A Critical Factor in Cancer Chemotherapy. American Journal of Medicine, 69, 585-594.
[8] Oncolor (2006) Lymphomes malins non hodgkiniens. Référentiels. 11.
[9] Thieblemont, C. and Coiffier, B. (2007) Lymphoma in Older Patients. Journal of Clinical Oncology, 25, 1916-1923.
[10] Sweet, D., Kinzie, J., Gaeke, M., et al. (1981) Survival of Patients with Localized Diffuse Histiocytic Lymphoma. Blood, 58, 1218-1223.
[11] Miller, T.P., Leblanc, M., Spier, C., et al. (2001) CHOP Alone Compared to CHOP plus Radiotherapy for Early Stage Aggressive Non-Hodgkin’s Lymphomas: Update of the Southwest Oncology Group (SWOG) Randomized Trial. Blood, 98, 724-730.
[12] Miller, T.P., Unger, J.M., Spier, C., et al. (2004) Effect of Adding Rituximab to Three Cycles of CHOP plus Involved Field Radiotherapy for Limited-Stage Aggressive Diffuse B-Cell Lymphoma (SWOG-0014) (Abstract). Blood, 104, 48-50.
[13] Shikama, N., Ikeda, H., Nakamura, S. and Oguchi, M. (2001) Localized Aggressive Non-Hodgkin’s Lymphoma of the Nasal Cavity: A Survey by the Japan Lymphoma Radiation Therapy Group. International Journal of Radiation Oncology, Biology, Physics, 51, 1228-1233.
[14] Miller, T.P. (2004) The Limits of Limited Stage Lymphoma. Journal of Clinical Oncology, 22, 2982-2984.
[15] Messori, A., Vaiani, M., Trippoli, S., et al. (2001) Survival in Patients with Intermediate or High Grade Non-Hodgkin’s Lymphoma: Meta-Analysis of Randomized Studies Comparing Third Generation Regimens with CHOP. British Journal of Cancer, 84, 303-307.
[16] Bauduer, F. (1998) Agents cytostatiques en hématologie. Encycl Med Chir, Traité d’Hématologie, 13-082-A-10, 22.
[17] Advani, R., Rosenberg, S.A. and Horning, S.J. (2004) Stage I and II Follicular Non-Hodgkin’s Lymphoma: Long-Term Follow-Up of No Initial Therapy. Journal of Clinical Oncology, 22, 1454-1459.
[18] Mac Manus, M.P., Rainer Bowie, C.A. and Hoppe, R.T. (1998) What Is the Prognosis for Patients Who Relapse after Primary Radiation Therapy for Early-Stage Low-Grade Follicular Lymphoma? International Journal of Radiation Oncology, Biology, Physics, 42, 365-371.
[19] Chen, M.G., Prosnitz, L.R., Gonzalez-Serva, A. and Fischer, D.B. (1979) Results of Radiotherapy in Control of Stage I and II Non-Hodgkin’s Lymphoma. Cancer, 43, 1245-1254.<1245::AID-CNCR2820430412>3.0.CO;2-Z
[20] McLaughlin, P., Fuller, L.M., Velasquez, W.S., Sullivan-Halley, J.A., Butler, J.J. and Cabanillas, F. (1986) Stage I-II Follicular Lymphoma: Treatment Results for 76 Patients. Cancer, 58, 1596-1602.<1596::AID-CNCR2820580803>3.0.CO;2-G
[21] Peterson, B.A., Petroni, G.R., Frizzera, G., Barcos, M., Bloomfield, C.D., Nissen, N.I., Hurd, D.D., Henderson, E.S., Sartiano, G.P., Johnson, J.L., Holland, J.F. and Gottlieb, A.J. (2003) Prolonged Single-Agent versus Combination Chemotherapy in Indolent Follicular Lymphomas: A Study of the Cancer and Leukemia Group B. Journal of Clinical Oncology, 21, 5-15.
[22] Young, R.C., Johnson, R.E., Canellos, G.P., Chabner, B.A., Brereton, H.D., Berard, C.W. and DeVita, V.T. (1977) Advanced Lymphocytic Lymphoma: Randomized Comparisons of Chemotherapy and Radiotherapy, Alone or in Combination. Cancer Treatment Reports, 61, 1153-1159.
[23] Schulz, H., Bohlius, J.F., Trelle, S., Skoetz, N., Reiser, M., Kober, T., Schwarzer, G., Herold, M., Dreyling, M., Hallek, M. and Engert, A. (2007) Immunochemotherapy with Rituximab and Overall Survival in Patients with Indolent or Mantle Cell Lymphoma: A Systematic Review and Meta-Analysis. Journal of the National Cancer Institute, 99, 706-714.
[24] Genentech-Idec (2001) Rituxan Letter Warns of Fatal Mucocutaneous Reactions. The Pink Sheet. F-D-C Reports, 63, 32.
[25] Davis, T.A., Maloney, D.G., Grillo-Lopez, A.J., White, C.A., Williams, M.E., Weiner, G.J., Dowden, S. and Levy, R. (2000) Combination Immunotherapy of Relapsed or Refractory Low-Grade or Follicular Non-Hodgkin’s Lymphoma with Rituximab and Interferon-Alpha-2a. Clinical Cancer Research, 6, 2644-2652.
[26] Foran, J.M., Rohatiner, A.Z., Coiffier, B., et al. (1999) Multicenter Phase II Study of Fludarabine Phosphate for Patients with Newly Diagnosed Lymphoplasmacytoid Lymphoma, Waldenstrom’s Macroglobulinemia, and Mantle-Cell Lymphoma. Journal of Clinical Oncology, 17, 546-553.
[27] Kalinka-Warzocha, E., Wajs, J., Lech-Maranda, E., Ceglarek, B., Holowiecki, J., Federowicz, I., Walewski, J., Czyz, J., Robak, T., Warzocha, K. and the Polish Lymphoma Research Group (2008) Randomized Comparison of Cladribine Alone or in Combination with Cyclophosphamide, and Cyclophosphamide, Vincristine and Prednisone in Previously Untreated Low-Grade B-Cell Non-Hodgkin Lymphoma Patients: Final Report of the Polish Lymphoma Research Group. Cancer, 113, 367-375.

Copyright © 2024 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.